Adsorption of globular proteins to vaccine adjuvants

被引:0
|
作者
Jang, M
Cho, I
Callahan, P
机构
[1] UNIV MISSOURI,DEPT CHEM,ROLLA,MO 65401
[2] PERKIN ELMER KOREA,SEOUL 137044,SOUTH KOREA
[3] BUCKS CHEMO,SEOUL 157210,SOUTH KOREA
来源
关键词
adsorption; aluminum phosphate gel; aluminum oxyhydroxide; bovine serum albumin (BSA); desorption; vaccine adjuvant; immunoglobulin G (IgG);
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The maximum adsorption/desorption conditions and the adsorption mechanism of globular proteins to vaccine adjuvants were determined. The maximum adsorption ratio of protein to the Al3+ content of aluminum oxyhydroxide and the optimal adsorption pH are 2:1 (mu g:mu g) for bovine serum albumin (BSA) at pH 6.0 and 2.5:1 (mu g:mu g) for immunoglobulin G (IgG) at pH 7.0, respectively. The maximum adsorption ratio onto aluminum phosphate gel was 1.5:1 (mu g Protein:mu g Al3+) at pH 5.0 for both BSA and IgG. Adsorption of the native globular proteins. BSA and IgG, to aluminum oxyhydroxide and aluminum phosphate gel was reversible as a function of pH. Complete desorption of these proteins from aluminum phosphate gel was observed at alkaline pH. whereas only 80 similar to 90% removal from aluminum oxyhydroxide was achieved with alkaline pH and 50 mM phosphate buffer. We conclude that electrostatic and hydrogen bonding interactions between the native proteins and adjuvants are important binding mechanisms for adsorption. and that the surface charge of the protein and the colloid components control the maximum adsorption conditions.
引用
下载
收藏
页码:346 / 351
页数:6
相关论文
共 50 条
  • [41] Molecular signatures of vaccine adjuvants
    Olafsdottir, Thorunn
    Lindqvist, Madelene
    Harandi, Ali M.
    VACCINE, 2015, 33 (40) : 5302 - 5307
  • [42] Vaccine adjuvants: Why and how
    Christensen, Dennis
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (10) : 2709 - 2711
  • [43] Vaccine adjuvants and macrophagic myofasciitis
    Siegrist, CA
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2003, 187 (08): : 1511 - 1518
  • [44] Adjuvants in tuberculosis vaccine development
    Moreno-Mendieta, Silvia A.
    Rocha-Zavaleta, Leticia
    Rodriguez-Sanoja, Romina
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2010, 58 (01): : 75 - 84
  • [45] Vaccine adjuvants: mechanisms and platforms
    Zhao, Tingmei
    Cai, Yulong
    Jiang, Yujie
    He, Xuemei
    Wei, Yuquan
    Yu, Yifan
    Tian, Xiaohe
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [46] SEPPIC vaccine Adjuvants for poultry
    Dupuis, L.
    Ascarateil, S.
    Aucouturier, J.
    Ganne, V.
    IMPACT OF EMERGING ZOONOTIC DISEASES ON ANIMAL HEALTH, 2006, 1081 : 202 - 205
  • [47] Aluminum Vaccine Adjuvants: Are they Safe?
    Tomljenovic, L.
    Shaw, C. A.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (17) : 2630 - 2637
  • [48] Cationic liposornes as vaccine adjuvants
    Christensen, Dennis
    Korsholm, Karen S.
    Rosenkrands, Ida
    Lindenstrom, Thomas
    Andersen, Peter
    Agger, Else Marie
    EXPERT REVIEW OF VACCINES, 2007, 6 (05) : 785 - 796
  • [49] Vaccine adjuvants and macrophagic myofasciitis
    Siegrist, CA
    ARCHIVES DE PEDIATRIE, 2005, 12 (01): : 96 - 101
  • [50] Recent advances in vaccine adjuvants
    Singh, M
    O'Hagan, DT
    PHARMACEUTICAL RESEARCH, 2002, 19 (06) : 715 - 728